PMID- 19900491
OWN - NLM
STAT- MEDLINE
DCOM- 20100223
LR  - 20091217
IS  - 1873-1686 (Electronic)
IS  - 0167-0115 (Linking)
VI  - 159
IP  - 1-3
DP  - 2010 Jan 8
TI  - The effect of glucagon-like peptide-2 on arterial blood flow and cardiac 
      parameters.
PG  - 67-71
LID - 10.1016/j.regpep.2009.11.001 [doi]
AB  - BACKGROUND: Glucagon-like peptide-2 (GLP-2) is known to increase mesenteric blood 
      flow. The aim of the study was to evaluate the effect of GLP-2 on blood flow in 
      different vascular sites, and dynamic changes in cardiac parameters. METHODS: 10 
      healthy volunteers were given 450 nmol subcutaneous (SC) GLP-2 or isotonic saline 
      (5 subjects) in a single blinded manner. During the following 90 min, blood flow 
      in the superior mesenteric artery (SMA), celiac artery (CA), renal artery (RA), 
      common carotid artery (CCA) was measured using Doppler ultrasound (US), and 
      cardiovascular variables were measured by impedance cardiography and finger 
      plethysmography. Plasma GLP-2 was measured at times 0, 30 and 60 min. RESULTS: 
      Compared to the placebo group, GLP-2 elicited a 27% decrease in the resistance 
      index (RI) and a 269.4% increase in Time Averaged Maximal Velocity (TAMV) in the 
      SMA (P<0.01). CA, RA and CCA: There were no significant changes in RI or TAMV in 
      the GLP-2 or placebo group, and no change in CA diameter. Cardiac parameters: 
      GLP-2 increased cardiac output (CO), stroke volume (SV) and heart rate (HR) 
      compared to baseline (respectively: 15.3, 4.81 and 8.2% (P<0.001, P<0.01 and 
      P<0.01)). The CO, SV and HR changes were not significantly different from the 
      placebo group. Mean plasma GLP-2 serum levels in the placebo group at times 0, 30 
      and 60 min were 22.8, 23.4 and 23.2 pmol/l. In the GLP-2 group 20.3, 1273 and 
      1725 pmol/l. CONCLUSION: SC GLP-2 increased SMA blood flow, as previously shown, 
      but elicited no changes in other vascular sites. CO and HR increased 
      significantly, presumably due to the increased mesenteric blood flow.
FAU - Bremholm, Lasse
AU  - Bremholm L
AD  - Department of Gastroenterology, Glostrup Hospital, University of Copenhagen, 
      Denmark. Hoersted-bremholm@webspeed.dk
FAU - Hornum, Mads
AU  - Hornum M
FAU - Andersen, Ulrik B
AU  - Andersen UB
FAU - Holst, Jens Juul
AU  - Holst JJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Regul Pept
JT  - Regulatory peptides
JID - 8100479
RN  - 0 (Glucagon-Like Peptide 2)
SB  - IM
MH  - Adult
MH  - Blood Flow Velocity/drug effects
MH  - Cardiography, Impedance
MH  - Female
MH  - Glucagon-Like Peptide 2/pharmacokinetics/*pharmacology
MH  - Heart Rate/*drug effects
MH  - Humans
MH  - Male
MH  - Single-Blind Method
MH  - Splanchnic Circulation/*drug effects
MH  - Stroke Volume/*drug effects
MH  - Ultrasonography, Doppler
MH  - Vascular Resistance/*drug effects
EDAT- 2009/11/11 06:00
MHDA- 2010/02/24 06:00
CRDT- 2009/11/11 06:00
PHST- 2009/05/11 00:00 [received]
PHST- 2009/10/09 00:00 [revised]
PHST- 2009/11/01 00:00 [accepted]
PHST- 2009/11/11 06:00 [entrez]
PHST- 2009/11/11 06:00 [pubmed]
PHST- 2010/02/24 06:00 [medline]
AID - S0167-0115(09)00223-7 [pii]
AID - 10.1016/j.regpep.2009.11.001 [doi]
PST - ppublish
SO  - Regul Pept. 2010 Jan 8;159(1-3):67-71. doi: 10.1016/j.regpep.2009.11.001.